(Q43048552)

12 November 2017

title

High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy (English)

1 reference

12 November 2017

0 references

1 reference

4

1 reference

12 November 2017

J M Vrolijk

1

1 reference

12 November 2017

F C Bekkering

series ordinal

2

1 reference

12 November 2017

J T Brouwer

series ordinal

3

1 reference

12 November 2017

S W Schalm

series ordinal

5

1 reference

12 November 2017

publication date

1 May 2003

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

10

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

205-209

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00408.X

10.1046/J.1365-2893.2003.00408.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference